Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial : European Journal of Cancer Prevention

Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid
Gynecological cancer

Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial

Afshani, Seyyedeh Maryama,b; Mirhassani, Reihanehc,d; Hosseini, Hamede; Hosseini, Reihanehf; Tehranian, Afsanehf; Malekzadeh, Rezag; Ostovar, Afshinh; Abdolghaffari, Amir Hosseind,i,j; Ghobadi, Mohammad Amina,b; Hedayatjoo, Behnazb; Hazegh Fetratjoo, Delaraa,b; Rezagholi, Zahraa,b; Anari, AmirHosseina,b; Moini, Ashraff

Author Information
European Journal of Cancer Prevention: November 2022 - Volume 31 - Issue 6 - p 558-567
doi: 10.1097/CEJ.0000000000000753
  • Buy

Abstract

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.